Eurofins Discovery is pleased to highlight its contribution to a new Nature publication, “De novo design of miniprotein agonists and antagonists targeting G protein–coupled receptors.” This work represents a significant advance in GPCR-targeted drug discovery, one of the most important and widely pursued areas in modern pharmacology.
The study demonstrates novel computational design approaches combined with high-throughput functional screening to generate miniproteins capable of selectively activating or inhibiting GPCRs. These engineered molecules show high affinity, potency, and specificity across receptors implicated in key therapeutic areas, including pain, cancer, metabolic diseases, and migraines.
Importantly, the research validates these designs through structural and functional characterisation, including cryo-EM confirmation and in vivo activity comparable to existing therapies. This highlights the growing potential of engineered biologics as precise modulators of GPCR function.
For biopharma and biotech clients, these advances underscore the need for robust, high quality assay platforms capable of resolving complex receptor pharmacology. Eurofins Discovery’s GPCR assay solutions are uniquely positioned to support this work, delivering ligand screening, functional profiling, and mechanistic insights across a broad spectrum of therapeutic modalities. The platform is well suited for emerging engineered modalities such as miniproteins, enabling teams to characterise their activity with the same rigor applied to small molecules, peptides, antibodies, and other novel scaffolds. This capability is essential for translating miniprotein innovations, highlighted in the recent Nature article, into viable therapeutic candidates.
As GPCR drug discovery continues to evolve, Eurofins Discovery remains committed to supporting clients with innovative technologies that accelerate the path from breakthrough science to clinical impact. To view the article, visit: De novo design of miniproteins targeting GPCRs | Nature
